The Lindsay Clancy Treatment Record: What It Shows About Midlevel Care, Adequate Drug Trials, and Clozapine
The treatment history of Lindsay Clancy, the Massachusetts nurse accused of killing her three children, should not be simplified into the claim that she was simultaneously taking 13 psychiatric drugs or that every prescribed dose was low. The publicly reported record is more complicated—and more instructive.
According to a Boston Globe review of court records, Clancy received more than 30 prescriptions involving 13 psychiatric medications during approximately four months. Those prescriptions came from psychiatrists, nurse practitioners or nurse clinicians, an emergency-department physician, and an inpatient psychiatric program. Some drugs were stopped, restarted, or prescribed at different doses. Trial testimony also indicates that some bottles remained relatively full, although her former husband testified that discontinued prescriptions were among those bottles.
Thus, the record documents extensive prescribing, but it does not establish that she took all 13 drugs together, took every prescription consistently, or completed adequate trials of most of them.
The corrected medication record
The following table reflects the Boston Globe’s 2026 timeline based on court records:
| Medication | Reported prescription history |
|---|---|
| Sertraline/Zoloft | 25 mg, increased to 50 mg |
| Lorazepam/Ativan | 0.5 mg, increased to 1 mg, reduced to 0.5 mg; later another 1-mg prescription |
| Diphenhydramine/Benadryl | 25 mg |
| Buspirone | 5 mg, with a repeated prescription |
| Trazodone | 50 mg; later 150 mg |
| Fluoxetine/Prozac | 10 mg |
| Zolpidem/Ambien | 5 mg |
| Mirtazapine/Remeron | Reported as 5 mg |
| Clonazepam/Klonopin | 0.5 mg |
| Quetiapine/Seroquel | 25 mg, increased to 100 mg and then 300 mg; subsequent prescriptions included 100 mg and 25 mg |
| Diazepam/Valium | Prescriptions at 2, 5, and 10 mg |
| Lamotrigine/Lamictal | 25 mg |
| Amitriptyline | 10 mg, increased to 20 mg |
There is one unresolved discrepancy. WBUR’s 2023 report, based on statements from Clancy’s attorney and earlier Globe reporting, listed hydroxyzine among the 13 drugs. The newer Globe court-record timeline lists diphenhydramine 25 mg instead. Without examining the underlying prescription records and trial exhibits, an article should not silently substitute one for the other or claim that both were necessarily prescribed.
Some trial coverage has described quetiapine as being titrated toward or up to 400 mg per day. The court-record timeline separately identifies 300-mg and 100-mg prescriptions, but it does not by itself establish exactly how those tablets were intended to be combined on every date. It is therefore safer to report the individual documented prescription strengths and acknowledge the reported 400-mg daily plan rather than assert an exact daily regimen.
The doses were not all low
Many of the initial prescriptions were low:
Sertraline 25 mg and fluoxetine 10 mg were introductory antidepressant doses.
Lamotrigine 25 mg was a required starting dose, not a therapeutic maintenance dose.
Quetiapine 25 mg is principally sedating and ordinarily too low for meaningful antipsychotic activity.
Buspirone 5 mg was a low dose.
Amitriptyline 10–20 mg was a low antidepressant dose and may have been intended primarily for sleep.
But it would be inaccurate to characterize every prescription as low. Quetiapine at 300 mg—and reportedly as much as 400 mg per day—is a substantial therapeutic dose. Trazodone 150 mg is within its antidepressant range. Diazepam 10 mg is not a trivial dose, particularly when considered alongside other sedating medications.
The real concern is not simply low dosing. It is the rapid sequence of starts, stops, dose changes, overlapping sedatives, multiple prescribers, and uncertain diagnostic framework.
Some psychiatric drugs require several weeks at a therapeutic dose before they can be fairly judged. Antidepressants generally do not demonstrate their full effect after a few tablets. Trial testimony reportedly established that Clancy took only seven sertraline tablets. That was exposure, but not an adequate antidepressant trial. WCVB trial coverage
Not every drug requires four weeks. Benzodiazepines and sleep medications act quickly. Antipsychotics can begin reducing agitation or psychotic symptoms earlier, although assessing their full effect ordinarily requires continued treatment at a therapeutic dose unless adverse effects demand discontinuation. Lamotrigine must be increased slowly because rapid titration raises the risk of a potentially life-threatening rash; it is not an emergency treatment for acute mania or psychosis.
A long prescription list therefore does not prove extensive treatment resistance. Treatment resistance can only be established when the diagnosis, adherence, therapeutic dose, duration, target symptoms, response, and reasons for discontinuation are known.
The record does not support blaming nurse practitioners alone
The corrected timeline weakens any simplistic claim that all the tentative or low-dose prescribing came from midlevel providers.
A psychiatrist reportedly prescribed sertraline, lorazepam, diphenhydramine, buspirone, lamotrigine, later diazepam, and amitriptyline. A nurse practitioner prescribed fluoxetine, zolpidem, mirtazapine, and clonazepam. A nurse clinician prescribed quetiapine and several diazepam prescriptions. An emergency physician and McLean Hospital clinicians prescribed trazodone, with McLean also reportedly prescribing lorazepam.
The more defensible criticism is therefore not that every physician acted boldly while every midlevel clinician was hesitant. The reported history does not show that. In fact, some of the more aggressive quetiapine escalation was reportedly undertaken by a nurse clinician.
The policy issue is whether an unstable postpartum patient with worsening insomnia, possible antidepressant activation, suicidal thoughts, thoughts involving her children, auditory phenomena, repeated emergency contacts, and numerous medication changes should have remained in fragmented outpatient medication management.
Nurse practitioners and physician assistants can provide valuable care to stable patients whose diagnoses and effective regimens are established. They can monitor response, renew treatment, manage straightforward adverse effects, and recognize when escalation is necessary. But suspected postpartum psychosis, bipolar disorder, rapidly changing symptoms, repeated treatment failure, suicidality, possible danger to children, or major diagnostic uncertainty should trigger immediate psychiatrist-led care—often in a hospital.
Psychiatrists complete medical school and a four-year psychiatry residency involving supervised management of psychosis, bipolar disorder, medical and neurological mimics, psychiatric emergencies, inpatient treatment, and complex pharmacology. Psychiatric nurse practitioners follow a different and generally shorter required clinical pathway; postgraduate NP residencies are not universally mandated. AAMC description of physician training AANP position on mandatory residencies
That difference in required training should matter most when the diagnosis is uncertain and the consequences of error are catastrophic.
Postpartum depression is not usually bipolar disorder—but bipolar disorder must be excluded
It is inaccurate to say that most women with postpartum depression have bipolar disorder. A more defensible and still clinically important finding is that approximately one in five postpartum women who screen positive for depression may have bipolar disorder. One major study found bipolar disorder in 22.6% of screen-positive women. Wisner and colleagues
That prevalence is high enough to require screening before repeatedly prescribing antidepressants. ACOG recommends bipolar screening before beginning pharmacological treatment for perinatal depression or anxiety because antidepressant monotherapy can precipitate mania, mixed symptoms, agitation, or cycling in susceptible patients. ACOG perinatal mental-health guidance
Severe insomnia, racing thoughts, agitation, emotional blunting, cognitive changes, suicidal thinking, unusual perceptual experiences, or marked deterioration after an antidepressant should prompt reassessment. The differential diagnosis includes bipolar-spectrum illness, postpartum psychosis, major depression with psychotic features, obsessive-compulsive disorder with intrusive but unwanted thoughts, medication-induced activation, substance effects, delirium, thyroid disease, autoimmune illness, and neurological disorders.
The clinician must distinguish distressing ego-dystonic thoughts—which a patient fears and does not want—from psychotic commands, delusional beliefs, impaired reality testing, or intent. That determination cannot safely be reduced to a short refill visit.
The danger should have been discussed plainly
Clancy was a labor-and-delivery nurse. Her medical training may have permitted a particularly technical discussion of diagnostic uncertainty and pharmacology, but every patient deserves the same essential candor.
When postpartum psychosis or severe bipolar illness is suspected, a clinician should say something like:
“This may be bipolar disorder or postpartum psychosis rather than ordinary anxiety or depression. These illnesses can impair judgment and, in rare cases, create danger to you or your children. Until we establish that you are stable, you should not be left alone with the children. Your family needs an emergency plan, and hospitalization may be the safest treatment.”
That is not an accusation that the mother intends to harm anyone. It is a medical safety warning, comparable to telling a patient with seizures not to drive until the condition is controlled.
Postpartum psychosis is a psychiatric emergency associated with elevated risks of suicide and harm to an infant. Published population estimates cannot predict an individual patient’s behavior, and sensational news cases should not replace a structured risk assessment. Nevertheless, previous tragedies demonstrate why clinicians must not minimize the potential consequences or rely on the patient’s profession, intelligence, usual personality, or love for her children as evidence that precautions are unnecessary. Review of postpartum psychosis management
The warning should be direct but nonjudgmental. Telling a patient that frightening thoughts may be symptoms of a treatable illness encourages disclosure. Telling her that she resembles mothers who murdered their children could produce shame and concealment. The safety message must be unmistakable without treating the patient as already guilty of a future act.
Clozapine: why not give it to everyone?
Clozapine has historically been used earlier, and sometimes as initial treatment, in parts of China. That experience raises an appropriate question: if clozapine helps many of the most difficult patients, why reserve it for treatment resistance?
A Chinese study randomized 160 treatment-naive patients with first-episode schizophrenia to clozapine or chlorpromazine. Clozapine produced faster remission—a median of eight weeks rather than 12—and greater early symptom improvement. At one year, however, remission rates were almost identical: 81% with clozapine and 79% with chlorpromazine. Initial 52-week study
At nine years, the groups had essentially identical proportions of time in remission, intermediate illness, and relapse. The initial advantage had not translated into clearly superior long-term outcomes for the average first-episode patient. Nine-year follow-up
That helps explain why clozapine is not used for everyone. The most effective rescue drug is not automatically the drug with the best initial risk-benefit ratio. Many patients respond to antipsychotics that are simpler to prescribe and monitor. Giving clozapine to everyone would expose responders to its additional burdens without necessarily improving their long-term outcome.
Although the FDA eliminated the formal Clozapine REMS reporting requirement in 2025, clozapine still carries risks of severe neutropenia, myocarditis and cardiomyopathy, seizures, orthostatic hypotension, sedation, major metabolic effects, excessive salivation, and severe gastrointestinal hypomotility. Constipation can progress to intestinal obstruction, ischemia, or death. The FDA continues to recommend absolute-neutrophil-count monitoring under the prescribing information. FDA REMS announcement FDA gastrointestinal warning
Clozapine is FDA-approved for treatment-resistant schizophrenia and for reducing recurrent suicidal behavior in schizophrenia or schizoaffective disorder. It is not FDA-approved specifically for bipolar disorder or postpartum psychosis.
But “not for everyone” should not mean “almost never” or “only after years of failure.”
A 2026 Chinese randomized study found that among first-episode psychosis patients who failed one adequate conventional antipsychotic trial, 62.5% responded to clozapine, compared with 31.7% receiving olanzapine and 44.7% receiving amisulpride. The investigators concluded that clozapine should be considered after one adequate antipsychotic failure in first-episode psychosis. 2026 SMART-CAT trial
That study involved first-episode psychosis, not specifically postpartum bipolar disorder, so it cannot be transferred uncritically to this case. Nevertheless, it strengthens the argument against prolonged delays once genuine antipsychotic nonresponse has been demonstrated.
Clozapine also has supportive, though less definitive, evidence in treatment-resistant bipolar disorder. A systematic review found reported improvements in mania, depression, psychosis, rapid cycling, hospitalization, aggression, self-harm, and suicidality, while noting important limitations in the evidence. Systematic review In a small prospective study of treatment-refractory mania, 72% of patients experienced marked improvement. Prospective mania study
For a patient with continuing severe mania or psychosis after two adequate, adherent, therapeutic trials of appropriate antipsychotic or mood-stabilizing strategies, clozapine should appear on the psychiatrist’s documented escalation list. It may warrant consideration earlier in an exceptionally dangerous or persistently psychotic case, but that decision should be made by a psychiatrist experienced with clozapine and its monitoring requirements.
The reported Clancy prescription history does not prove failure of two adequate antipsychotic trials. Quetiapine was the only clearly reported antipsychotic, and its dose changed repeatedly before it was discontinued. The failure may therefore have occurred before the formal treatment-resistance threshold: the system apparently never completed an orderly sequence of two adequate antipsychotic trials from which a clear clozapine decision could be made.
Clozapine was not the only escalation option
Postpartum psychosis is generally treated as an emergency with hospitalization, an antipsychotic, and frequently lithium. Electroconvulsive therapy is an important option when symptoms are life-threatening, catatonic, severely depressive, manic, psychotic, or insufficiently responsive to medication. ECT may be particularly valuable when speed matters because clozapine requires titration and extensive monitoring.
In a sequential-treatment study of postpartum psychosis, treatment involving a benzodiazepine, antipsychotic, and lithium produced remission in 98.4% of patients, with lithium providing stronger maintenance protection than antipsychotic monotherapy. Postpartum psychosis treatment study
Antipsychotic augmentation is also established for treatment-resistant unipolar depression. Television advertisements for Vraylar, Caplyta, and Rexulti reflect legitimate approved indications, but advertisements are not diagnostic algorithms. Generic aripiprazole is FDA-approved as adjunctive treatment for major depressive disorder, while olanzapine is another potent and inexpensive antipsychotic with considerable metabolic risks. Aripiprazole prescribing information
Antidepressant augmentation, acute bipolar-mania treatment, and treatment of postpartum psychosis are not interchangeable strategies. The diagnosis must determine the treatment.
The policy lesson
No retrospective article can prove that one medication, hospitalization, or specialist would have prevented these deaths. Nor do prescriptions alone establish negligence, causation, or what Clancy’s mental state was when the children died. Those issues must be determined from the complete medical record and evidence presented in court.
The reported treatment history nevertheless supports several policy conclusions:
Stable patients with established diagnoses and effective regimens can often be managed by experienced nurse practitioners within a collaborative system.
Rapid deterioration, suspected bipolar disorder or postpartum psychosis, suicidality, thoughts involving children, hallucinations, or repeated medication failures require psychiatrist-led care.
Bipolar disorder should be screened for before antidepressants are repeatedly prescribed.
Medication trials should identify target symptoms, intended dose, expected duration, adherence, response, adverse effects, and the next step if treatment fails.
A list of prescriptions must not be confused with medications actually taken or adequate therapeutic trials.
Child-safety precautions and hospitalization should not wait until a patient states an immediate, detailed plan.
Lithium, an appropriate antipsychotic, and ECT should be considered promptly when indicated.
Clozapine should enter the documented escalation discussion after adequate treatment failures rather than being indefinitely avoided because it is difficult to manage.
Responsibility for a complex patient must rest with an identifiable physician-led team rather than being fragmented among multiple prescribers.
The strongest criticism of the Clancy treatment record is not that every dose was low or that nurse practitioners alone caused the problem. The record does not support either claim. The stronger argument is that an unstable postpartum patient moved through numerous prescriptions and multiple levels of care without a sufficiently coherent diagnostic, safety, and escalation plan.
That is precisely the kind of case in which the difference between routine medication management and specialist psychiatric leadership can become a matter of life and death.
No comments:
Post a Comment